About HiFiBiO
HiFiBiO is a company based in Paris (France) founded in 2013 by Liang Schweizer. HiFiBiO has raised $179.5 million across 3 funding rounds from investors including Kite Pharma, Legend Holdings and Mirae Asset Financial Services. HiFiBiO has completed 1 acquisition, including H-Immune. HiFiBiO offers products and services including DIS® Platform, EMUNKITUG, and HFB200604. HiFiBiO operates in a competitive market with competitors including GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
- Headquarter Paris, France
- Founders Liang Schweizer
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website hifibio.com
- Social LinkedIn X
- Legal Name Hifibio Therapeutics, Inc.
- Total Equity Funding$179.5M (USD)
in 3 rounds
- Latest Funding Round$75M (USD), Series D
Jun 2021
- InvestorsKite Pharma
& 19 more
- Investments & Acquisitions
Products & Services of HiFiBiO
HiFiBiO offers a comprehensive portfolio of products and services, including DIS® Platform, EMUNKITUG, and HFB200604.
Enables drug discovery through single cell tech and AI analytics
Antibody for potential oncology treatment in clinical trials
Antibody targeting inflammatory and immunology diseases
Funding Insights of HiFiBiO
HiFiBiO has successfully raised a total of $179.5M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $75 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $179.5M
- Total Rounds 3
- Last Round Series D — $75M
- First Round $37.5M
(May 2018)
- Investors Count 20
All 3 funding rounds of HiFiBiO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $75M | Series D | – | Mirae Asset Financial Services | |
| Aug 2019 | $67M | Series C | – | IDG Capital | |
| May 2018 | $37.5M | Series B | – | Sequoia Capital China, LYFE Capital |
20 investors in total: 20 institutional.
Investors in HiFiBiO
HiFiBiO has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include Kite Pharma, Legend Holdings and Mirae Asset Financial Services.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | - | |
- | – | sherpahp.com | - | |
Tech & Offline focused early & growth stage VC firm investing in China | – | maisoncapital.com | Shenzhen, China | |
Venture capital fund focused on healthcare sectors | – | grandmountcapital.com | Jing'an, China | |
A corporation focused on fostering innovation and technology ecosystems. | 2002 | hkstp.org | Hong Kong, Hong Kong S.A.R. | |
A venture capital firm focused on biotech innovation investments. | 2018 | trinity-fund.com | Beijing, China | |
Venture capital firm | – | idgcapital.com | New York, United States | |
Chinese startups are funded and incubated by Legend Star. | – | legendstar.com.cn | Beijing, China | |
- | – | saiccapital.com | - | |
Multistage investments are directed toward technology, healthcare, and climate sectors. | – | b.capital | Manhattan Beach, United States |
Investor details for HiFiBiO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HiFiBiO
27 people are tracked at HiFiBiO (8 in leadership, 12 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Liang Schweizer | Co-Founder & CEO | Leadership |
Yun-Yueh Lu | Senior Director, Discovery Biology & In Vivo Pharmacology | Leadership |
Jinping Gan | VP, Global Head of Research | Leadership |
Chao Kong | Director of China External Innovation | Leadership |
Roshan Kumar | Senior Director, External Innovation | Leadership |
Francisco Adrian | Chief Scientific Officer | Leadership |
Vincent Tse | Senior Director, Staff & Strategy | Leadership |
He Zhou | Executive Director, Asia-Pacific External Innovation | Leadership |
Leslie Kean | Scientific Advisor | Board & advisors |
Michael Croft | Scientific Advisor | Board & advisors |
Sebastian Amigorena | Scientific Advisor | Board & advisors |
Aurélien Marabelle | Scientific Advisor | Board & advisors |
Andrew Griffiths | Scientific Founder | Board & advisors |
Robert Nicol | Scientific Founder | Board & advisors |
Jérôme Bibette | Scientific Founder | Board & advisors |
Bradley Bernstein | Scientific Founder | Board & advisors |
Dave Weitz | Scientific Founder | Board & advisors |
Giovanni Abbadessa | Scientific Advisor | Board & advisors |
Peter Ho | Scientific Advisor | Board & advisors |
Wendye Robbins | Scientific Advisor | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for HiFiBiO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HiFiBiO
HiFiBiO has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include H-Immune.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developing MAb immunotherapies to treat cancer | h-immune.com | Paris, France | 2016 | Oct 2018 | •••• |
Complete acquisition details for HiFiBiO
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of HiFiBiO
4 dated milestones of HiFiBiO across 8 years, from founding to its latest funding, stage changes and deals.
- Founded HiFiBiO is founded.
- Funding First funding round of $37.5M.
- Acquisition Acquires H-Immune.
- Funding Latest funding round, Series D, of $75.0M.
Competitors of HiFiBiO
HiFiBiO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| mazetx.com | 2018 | Redwood, United States | $496M | 111 | Genetic biomarkers are developed for neurological, metabolic, and renal diseases. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. |
Detailed competitors of HiFiBiO
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of HiFiBiO
The website of HiFiBiO (hifibio.com) receives about 2K visits a month and ranks #8,611,201 among all websites worldwide, #7,428 in Biotechnology and Pharmaceuticals.
- Monthly visits2K
▲ 10.6% vs previous month
- Global rank#8,611,201
among all websites
- Category rank#7,428
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.9
- Average visit37 sec
- DevicesDesktop 35% · Mobile 65%
Latest news on Hifibio
Complete news archive for HiFiBiO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to HiFiBiO
10 companies that operate in the same segment as HiFiBiO (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about HiFiBiO
HiFiBiO was founded in 2013 and raised its 1st funding round 5 years after it was founded.
HiFiBiO is headquartered in Paris, France.
Liang Schweizer is the current CEO of HiFiBiO. They have also founded this company.
HiFiBiO is a funded company, having raised a total of $179.5M across 3 funding rounds to date. The company's 1st funding round was a Series B of $37.5M, raised on May 2018.
HiFiBiO was established in 2013 in Paris, France, within the biotechnology sector. A platform is provided for antibody-based drug discovery, where entire B cell populations are screened through high-throughput, single-cell, functional methods. Next-generation sequencing and rapid DNA synthesis are integrated to target rare antibodies. Operations emphasize efficient identification and development of therapeutic candidates for pharmaceutical applications.
HiFiBiO's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
HiFiBiO offers DIS® Platform, EMUNKITUG, and HFB200604.
HiFiBiO has made 1 acquisition, including H-Immune.
HiFiBiO has 20 investors. Key investors include Kite Pharma, Legend Holdings, Mirae Asset Financial Services, Sequoia Capital, and Sherpa Healthcare Partners.
HiFiBiO operates through Hifibio Therapeutics, Inc..